drugset / Trial / NCT06695013
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore whether adding immunotherapy bridging treatment for low-risk refractory/relapsed B-NHL can demonstrate better outcomes, in order to find the most effective treatment plan for low-risk patients.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2026-11-20
- Completion
- 2027-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |